about
Targeting antibacterial agents by using drug-carrying filamentous bacteriophagesPharmGKB summary: very important pharmacogene information for N-acetyltransferase 2Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, PeruEffect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review.Measuring health-related quality of life in tuberculosis: a systematic review.Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in KoreaDelayed diagnosis of sarcoidosis is common in BrazilA retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergyA prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India.Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan populationHepatic safety of antibiotics used in primary careDrug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.Clinical applications of drug desensitization in the Asia-Pacific region.Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin.A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage.Successful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis.Acute Psychosis after Recent Isoniazid Initiation.Knowledge of tuberculosis-treatment prescription of health workers: a systematic reviewNovel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study.Biomarkers of oxidative stress and personalized treatment of pulmonary tuberculosis: emerging role of gamma-glutamyltransferase.Adverse Drug Reaction Profile in Patients on Anti-tubercular Treatment Alone and in Combination with Highly Active Antiretroviral Therapy.Probability of negative mycobacterium tuberculosis complex cultures based on time to detection of positive cultures: a multicenter evaluation of commercial-broth-based culture systemsA diagnostic dilemma: infectious versus noninfectious multifocal choroiditis with panuveitis.Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patientsChemotherapeutic interventions against tuberculosisHIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.An analysis of serious adverse drug reactions at a tertiary care teaching hospitalRifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis.Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs.The risk of tuberculosis in patients treated with TNF antagonists.Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future.Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.Diagnosis of Ocular Tuberculosis.Novel Thiazolidinone-Azole Hybrids: Design, Synthesis and Antimycobacterial Activity Studies.Controversies in ocular tuberculosis.A 37-year-old woman presenting with impaired visual function during antituberculosis drug therapy: a case reportStriking the right immunological balance prevents progression of tuberculosis.Update on the management of antibiotic allergyComparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.
P2860
Q24548258-C388FBA5-6F52-4061-9F65-F5F742535E8DQ27011622-EAC8168E-31CB-4521-863F-E842D853EF30Q28478014-BAAB6C54-D266-43A2-85E8-BC878E24D2BAQ30240445-A4CF97FD-3744-4760-A75F-8010D3126291Q30486330-47D0E982-0E9C-4180-A89D-11E4B8B3E704Q33567352-2D9FB158-F752-434E-AF56-38808A44DE51Q33824238-0751C61E-1DBC-4AC9-B948-52158E114844Q33974514-7D8DDFFB-E4F1-48A2-B6E1-7104F0D89419Q34194183-EA2E7810-7DA7-456E-A477-97089A642019Q34986858-DB7A5626-EF97-4F05-97FE-0F1470EE1E6DQ35037383-E7B0E43A-4918-437C-BAFE-B276AD537098Q35094201-230AC60E-7478-4647-BD0D-85976E844EFFQ35502326-3E813DAE-FEB9-4F05-B09D-4A47B33A309EQ35657599-9E6C7985-6886-47A8-AB4B-3872DBE72FD2Q35716507-1D02208B-F36D-4874-A7B1-F0B04BB4924DQ35833154-7CC6ED4E-B3A2-4B85-A3D0-58616A044AFEQ35871161-60499CE5-AC21-41E5-8B63-4E0F98678908Q35918254-EBA5D75D-CA69-4F23-A510-4DC36F56B3E3Q35929843-41F1135D-A858-48C4-A505-8EAA45C0D131Q35950533-8247EA96-5851-4820-8AF8-C3FA00401B7BQ35960107-DDA8E354-8AC4-421C-A6C9-C639D03E9302Q36221959-A4444768-40B2-408B-AA69-4BEE67D0E28DQ36277056-F27A0B8A-4E1C-4C3E-855F-7A382B39BFDEQ36707188-BDCEC6ED-8A59-4B9A-8596-76B445162C48Q37114268-BAD4A359-8D41-4D1A-AF47-7E5BF0991858Q37148764-7C076C59-307C-4B38-BBAE-4871DC509203Q37287701-6EB9E5AA-4575-48B0-9513-01B2E0DD87C6Q37364594-61B3099D-FBC6-4EE5-B63E-A436D1E0926CQ37425851-55951950-5184-4D1D-8401-F822FD24872AQ37810480-CB799FCD-B542-48A4-850C-E79E5B5A50E0Q37877262-ADA24DF9-A086-4BCB-A41D-A0F15DE28E3AQ38003494-16B41C5F-4EB0-49B3-A4D9-986E138FEA73Q38803026-DF0BD54A-0C89-4147-A75A-CD0D4E9892B5Q38886299-3C6D977C-55C8-4053-ADA3-A7790E9FE565Q38938451-9B3ABEFE-3482-4C1A-B971-6F386057D222Q38999122-401F4F00-D739-47FD-B175-30ECA9B93067Q39387859-9E55DB0D-ED5E-4C69-A61D-68376247912AQ39437320-BECFE28C-C95C-47C3-AA36-5F7A7DF9F438Q39830842-A56DA4CB-B663-4950-B166-3AFB7687610AQ40680333-E382828E-8062-4CE0-A9E0-8997BF627497
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Adverse reactions to first-line antituberculosis drugs.
@ast
Adverse reactions to first-line antituberculosis drugs.
@en
Adverse reactions to first-line antituberculosis drugs.
@nl
type
label
Adverse reactions to first-line antituberculosis drugs.
@ast
Adverse reactions to first-line antituberculosis drugs.
@en
Adverse reactions to first-line antituberculosis drugs.
@nl
prefLabel
Adverse reactions to first-line antituberculosis drugs.
@ast
Adverse reactions to first-line antituberculosis drugs.
@en
Adverse reactions to first-line antituberculosis drugs.
@nl
P2860
P356
P1476
Adverse reactions to first-line antituberculosis drugs.
@en
P2093
Eric J Forget
P2860
P304
P356
10.1517/14740338.5.2.231
P407
P50
P577
2006-03-01T00:00:00Z